Pluristem Therapeutics Inc (PSTI)

[SuperSquirrel]

"A company can't necessarily patent a mesenchymal cell, but certainly the process, the method of use and, in some cases, the composition of the final product can be patented. Of course, there will be emerging patent battles among players in the space. If we compare what Osiris Therapeutics Inc. (OSIR), Athersys Inc. (ATHX), Pluristem Therapeutics Inc. (PSTI) and Mesoblast are doing, they all have different variations of an allogeneic product (using cells from the same species). But there is enough proprietary IP in what they're doing that these products can be treated like traditional pharmaceuticals with regard to their proprietary natures. "...

" If allo wins, that tells me that Mesoblast, Athersys, Pluristem and even Osiris are potentially big winners in this space. "

http://wire.kapitall.com/investment-idea/position-yourself-for-big-returns-in-the-stem-cell-space-jason-kolbert/